115 related articles for article (PubMed ID: 22634008)
21. Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo.
Kojiro S; Yano H; Ogasawara S; Momosaki S; Takemoto Y; Nishida N; Kojiro M
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):129-37. PubMed ID: 16706824
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
Li WC; Ye SL; Sun RX; Liu YK; Tang ZY; Kim Y; Karras JG; Zhang H
Clin Cancer Res; 2006 Dec; 12(23):7140-8. PubMed ID: 17145839
[TBL] [Abstract][Full Text] [Related]
23. Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells.
Kondo M; Nagano H; Wada H; Damdinsuren B; Yamamoto H; Hiraoka N; Eguchi H; Miyamoto A; Yamamoto T; Ota H; Nakamura M; Marubashi S; Dono K; Umeshita K; Nakamori S; Sakon M; Monden M
Clin Cancer Res; 2005 Feb; 11(3):1277-86. PubMed ID: 15709199
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3.
Chen KF; Tai WT; Liu TH; Huang HP; Lin YC; Shiau CW; Li PK; Chen PJ; Cheng AL
Clin Cancer Res; 2010 Nov; 16(21):5189-99. PubMed ID: 20884624
[TBL] [Abstract][Full Text] [Related]
25. Cyclooxygenase-2 inhibitor and interferon-beta synergistically induce apoptosis in human hepatoma cells in vitro and in vivo.
Nakamoto N; Higuchi H; Kanamori H; Kurita S; Tada S; Takaishi H; Toda K; Yamada T; Kumagai N; Saito H; Hibi T
Int J Oncol; 2006 Sep; 29(3):625-35. PubMed ID: 16865278
[TBL] [Abstract][Full Text] [Related]
26. Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells.
Chun E; Lee KY
Biochem Biophys Res Commun; 2004 Mar; 315(3):771-9. PubMed ID: 14975768
[TBL] [Abstract][Full Text] [Related]
27. Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma.
Sieghart W; Pinter M; Dauser B; Rohr-Udilova N; Piguet AC; Prager G; Hayden H; Dienes HP; Dufour JF; Peck-Radosavljevic M
J Hepatol; 2012 Sep; 57(3):592-9. PubMed ID: 22634341
[TBL] [Abstract][Full Text] [Related]
28. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
29. Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells.
Murakami M; Kobayashi S; Marubashi S; Tomimaru Y; Noda T; Wada H; Eguchi H; Takeda Y; Tanemura M; Umeshita K; Doki Y; Mori M; Nagano H
Ann Surg Oncol; 2011 Feb; 18(2):589-96. PubMed ID: 20811948
[TBL] [Abstract][Full Text] [Related]
30. Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
Mao J; Yang H; Cui T; Pan P; Kabir N; Chen D; Ma J; Chen X; Chen Y; Yang Y
Eur J Pharmacol; 2018 Aug; 832():39-49. PubMed ID: 29782854
[TBL] [Abstract][Full Text] [Related]
31. Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins.
Wada H; Nagano H; Yamamoto H; Arai I; Ota H; Nakamura M; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Doki Y; Dono K; Nakamori S; Sakon M; Monden M
Oncol Rep; 2007 Oct; 18(4):801-9. PubMed ID: 17786339
[TBL] [Abstract][Full Text] [Related]
32. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.
Shimizu S; Takehara T; Hikita H; Kodama T; Miyagi T; Hosui A; Tatsumi T; Ishida H; Noda T; Nagano H; Doki Y; Mori M; Hayashi N
J Hepatol; 2010 May; 52(5):698-704. PubMed ID: 20347499
[TBL] [Abstract][Full Text] [Related]
33. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
[TBL] [Abstract][Full Text] [Related]
34. Combination of interferon-α and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro.
Yin H; Xie F; Zhang J; Yang Y; Deng B; Sun J; Wang Q; Qu X; Mao H
Cancer Lett; 2011 Jul; 306(1):34-42. PubMed ID: 21474236
[TBL] [Abstract][Full Text] [Related]
35. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis.
Qi R; An H; Yu Y; Zhang M; Liu S; Xu H; Guo Z; Cheng T; Cao X
Cancer Res; 2003 Dec; 63(23):8323-9. PubMed ID: 14678992
[TBL] [Abstract][Full Text] [Related]
36. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy.
Wu JM; Sheng H; Saxena R; Skill NJ; Bhat-Nakshatri P; Yu M; Nakshatri H; Maluccio MA
Cancer Lett; 2009 Jun; 278(2):145-155. PubMed ID: 19303700
[TBL] [Abstract][Full Text] [Related]
37. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
38. Expression level of Bcl-XL critically affects sensitivity of hepatocellular carcinoma cells to LIGHT-enhanced and interferon-gamma-induced apoptosis.
Li J; Shen F; Wu D; Wei LX; Wang YZ; Shi LH; Zou Y; Wu MC
Oncol Rep; 2007 May; 17(5):1067-75. PubMed ID: 17390046
[TBL] [Abstract][Full Text] [Related]
39. A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins.
Nishikawa T; Nakajima T; Moriguchi M; Jo M; Sekoguchi S; Ishii M; Takashima H; Katagishi T; Kimura H; Minami M; Itoh Y; Kagawa K; Okanoue T
J Hepatol; 2006 Jun; 44(6):1074-82. PubMed ID: 16481065
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
